REG - Novacyt S.A. - Liquidity Agreement and Total Voting Rights

Novacyt SAAnnouncement

01/02/2023 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230201:nRSA6211Oa&default-theme=true

RNS Number : 6211O  Novacyt S.A.  01 February 2023

 

Novacyt S.A.

 

("Novacyt", the "Company" or the "Group")

 

Liquidity Agreement Monthly Update and

Total Voting Rights

 

Paris, France and Eastleigh, UK - 1 February 2023 - Novacyt (EURONEXT
GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical
diagnostics, announces its monthly update in relation to ordinary shares
traded under its ongoing liquidity agreement with Invest Securities SA (the
"Liquidity Agreement"). The Liquidity Agreement is governed by French law and
is further summarised in the 'notes for editors' section below.

 

During the period from 1 January to 31 January 2023, Invest Securities
purchased 103,999 ordinary shares at a maximum price of €1.77 and a minimum
price of €0.80 and sold 88,379 ordinary shares at a maximum price of €1.65
and a minimum price of €0.81 under the Liquidity Agreement. The total number
of ordinary shares in the Company, which are held in treasury as at close of
business on 31 January 2023, is 32,613.

 

Total Voting Rights

 

The total number of ordinary shares in the Company is 70,626,248. This figure
may be used by shareholders as the denominator for calculations by which they
will determine if they are required to notify their interest in, or a change
to their interest in, the Company pursuant to Article L. 223-7 of the French
Commercial Code and the Company's Articles. The Company is not subject to the
disclosure guidance and transparency rules made by the Financial Conduct
Authority under Part VI of FSMA.

 

- End -

 

For further information, please refer to www.novacyt.com
(http://www.novacyt.com/) or contact:

 

Contacts

Novacyt SA

James Wakefield, Non-Executive Chairman

James McCarthy, Acting Chief Executive Officer

+44 (0)1276 600081

 

SP Angel Corporate Finance LLP (Nominated Adviser and Broker)

Matthew Johnson / Charlie Bouverat (Corporate Finance)

Vadim Alexandre / Rob Rees (Corporate Broking)

+44 (0)20 3470 0470

 

Numis (Joint Broker)

Freddie Barnfield / James Black

+44 (0)20 7260 1000

 

Allegra Finance (French Listing Sponsor)

Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10

r.durgetto@allegrafinance.com (mailto:r.durgetto@allegrafinance.com) /
y.petit@allegrafinance.com (mailto:y.petit@allegrafinance.com)

 

FTI Consulting (International)

Victoria Foster Mitchell / Alex Shaw

+44 (0)20 3727 1000

victoria.fostermitchell@fticonsulting.com
(mailto:victoria.fostermitchell@fticonsulting.com) /
Alex.Shaw@fticonsulting.com (mailto:Alex.Shaw@fticonsulting.com) /
Novacyt.group@fticonsulting.com (mailto:Novacyt.group@fticonsulting.com)

 

FTI Consulting (France)

Arnaud de Cheffontaines

+33 (0)147 03 69 48

arnaud.decheffontaines@fticonsulting.com
(mailto:arnaud.decheffontaines@fticonsulting.com)

 

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an
increasing portfolio of in vitro and molecular diagnostic tests. Its core
strengths lie in diagnostics product development, commercialisation, contract
design and manufacturing. The Company supplies an extensive range of
high-quality assays and reagents worldwide. The Group directly serves
microbiology, haematology and serology markets as do its global partners,
which include major corporates

 

For more information, please refer to the website: www.novacyt.com
(http://www.novacyt.com)

 

Further information on the Liquidity Agreement

On 12 September 2016, the Company and Invest Securities entered into the
Liquidity Agreement pursuant to which Invest Securities provides liquidity
services in relation to the ordinary shares to the Company. Invest Securities
may purchase ordinary shares on behalf of the Company under the agreement,
subject to approval from Shareholders as to the price at which ordinary shares
can be brought back and the aggregate amount that the Company may provide to
Invest Securities to purchase such ordinary shares.

 

Shareholder approval was granted at the Shareholders' meeting held on 20 July
2022 for the purchase of ordinary shares by Invest Securities under the
agreement at a maximum purchase price per ordinary shares of €12.00 for an
aggregate maximum purchase price of €200,000 and for 18 months from the date
of the approval. Under the agreement, Invest Securities must act completely
independently of the Company and the Company must not communicate with the
employees of Invest Securities who are responsible for performing the
agreement. Invest Securities is paid €10,000 per annum for its services
under the liquidity agreement. The agreement has an initial term of two years,
with a rolling extension of one year thereafter. The agreement can be
terminated by either party at the end of each such period subject to two
months' prior notice. The Liquidity Agreement is governed by French law.
Ordinary shares purchased by Invest Securities are either cancelled or held as
treasury shares (which are non-voting and do not rank for dividends).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRXFLFBXLLFBBE